Skip to main content
SpringerLink
Log in

Lansoprazole

In the Treatment of Gastro-oesophageal Reflux Disease in Children and Adolescents

  • Adis Drug Profile
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

▴ Lansoprazole is a proton pump inhibitor that inactivates the H+/K+-ATPase pump in parietal cells, thus inhibiting gastric acid secretion and increasing intragastric pH.

▴ In an open-label, uncontrolled trial in children aged 1–11 years with gastro-oesophageal reflux disease (GORD), treatment with lansoprazole 15 or 30mg (depending on weight) once daily for 8–12 weeks improved symptoms compared with baseline in 76% of patients (47 of 62) based on patient diaries and healed erosive oesophagitis (confirmed endoscopically) in all 27 children who had it at baseline.

▴ In adolescents aged 12–17 years with GORD, 8 weeks’ treatment with lansoprazole 15mg (in 64 patients with nonerosive disease) or 30mg (in 23 patients with erosive oesophagitis) once daily reduced the frequency and severity of symptoms by 63% and 69% compared with baseline, based on patient diaries. In this open-label, uncontrolled trial, 96% of evaluable patients with erosive disease (21 of 22) had mucosal healing by week 8, as confirmed by endoscopy; mucosal healing did not occur after an additional 4 weeks’ treatment in one patient.

▴ Lansoprazole was generally well tolerated in children and adolescents, with the most common treatment-related adverse events being gastrointestinal events and headache.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Hassall E. Decisions in diagnosing and managing chronic gastroesophageal reflux disease in children. J Pediatr 2005; 146 (3 Suppl.): S3–S12

    Article  PubMed  Google Scholar 

  2. Rudolph CD, Mazur LJ, Liptak GS, et al. Pediatric GE reflux clinical practice guidelines. J Pediatr Gastroenterol Nutr 2001; 35 Suppl. 2: S1–31

    Article  Google Scholar 

  3. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005 Jan; 100(1): 190–200

    Article  PubMed  Google Scholar 

  4. Barradell LB, Faulds D, McTavish D. Lansoprazole: a review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs 1992; 44(2): 225–50

    Article  PubMed  CAS  Google Scholar 

  5. Spencer CM, Faulds D. Lansoprazole: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders. Drugs 1994; 48(3): 404–30

    Article  PubMed  CAS  Google Scholar 

  6. Langtry HD, Wilde MI. Lansoprazole: an update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Drugs 1997; 54(3): 473–500

    Article  PubMed  CAS  Google Scholar 

  7. Matheson AJ, Jarvis B. Lansoprazole: an update of its place in the management of acid-related disorders. Drugs 2001; 61(12): 1801–33

    Article  PubMed  CAS  Google Scholar 

  8. TAP Pharmaceutical Products Inc. Prevacid (lansoprazole) package insert (US). July 2004 [online]. Available from URL: http://www.tap.com [Accessed 2005 Sep 25]

  9. Gremse D, Winter H, Tolia V, et al. Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2002; 35 Suppl. 4: S319–26

    Article  PubMed  CAS  Google Scholar 

  10. Gunasekaran T, Gupta S, Gremse D, et al. Lansoprazole in adolescents with gastroesophageal reflux disease: pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability. J Pediatr Gastroenterol Nutr 2002; 35 Suppl. 4: S327–35

    Article  PubMed  CAS  Google Scholar 

  11. Fiedorek S, Tolia T, Gold BD, et al. Efficacy and safety of lansoprazole in adolescents with symptomatic erosive and non-erosive gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2005 Mar; 40(3): 319–27

    Article  PubMed  CAS  Google Scholar 

  12. Book L, Chiu Y-L, Pilmer B, et al. Effect of lansoprazole on intraesophageal pH in children with pathologic acid reflux [abstract no. S1276]. Gastroenterology 2002 Apr; 122 Suppl. 1: A197. Plus poster presented at Digestive Disease Week; 2002 May 19–22; San Francisco (CA)

    Google Scholar 

  13. Miner P, Katz PO, Chen Y, et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003; 98(12): 2616–20

    Article  PubMed  CAS  Google Scholar 

  14. Armstrong D, Marshall JK, Chiba N, et al. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults-update 2004 [online]. Available from URL: http://www.cag-acg.org [Accessed 2005 Sep 23]

  15. Stolte M, Meining A, Seifert E, et al. Treatment with lansoprazole also induces hypertrophy of the parietal cells of the stomach. Pathol Res Pract 2000; 196: 9–13

    Article  PubMed  CAS  Google Scholar 

  16. Stolte M, Vieth M, Schmitz JM, et al. Effects of long-term treatment with proton pump inhibitors in gastro-oesophageal reflux disease on the histological findings in the lower oesophagus. Scand J Gastroenterol 2000; 35: 1125–30

    Article  PubMed  CAS  Google Scholar 

  17. Faure C, Michaud L, Shaghaghi EK, et al. Lansoprazole in children: pharmacokinetics and efficacy in reflux oesophagitis. Aliment Pharmacol Ther 2001 Sep; 15(9): 1397–402

    Article  PubMed  CAS  Google Scholar 

  18. Tran A, Rey E, Pons G, et al. Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. Clin Pharmacol Ther 2002 May; 71(5): 359–67

    Article  PubMed  CAS  Google Scholar 

  19. Freston JW, Chiu Y-L, Mulford DJ, et al. Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects. Aliment Pharmacol Ther 2003 Feb 1; 17: 361–7

    Article  PubMed  CAS  Google Scholar 

  20. Gremse DA, Donnelly JR, Kukulka MJ, et al. A novel option for dosing of proton pump inhibitors: dispersion of lansoprazole orally disintegrating tablet in water via oral syringe. Aliment Pharmacol Ther 2004 Jun 1; 19(11): 1211–5

    Article  PubMed  CAS  Google Scholar 

  21. Tolia V, Ferry G, Gunasekaran T, et al. Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr 2002; 35 Suppl. 4: S308–18

    Article  PubMed  CAS  Google Scholar 

  22. Franco MT, Salvia G, Terrin G, et al. Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood. Dig Liver Dis 2000 Nov; 32(8): 660–6

    Article  PubMed  CAS  Google Scholar 

  23. Tolia V, Johnston G, Stolle J, et al. Flavor and taste of lansoprazole strawberry-flavored delayed-release oral suspension preferred over ranitidine peppermint-flavored oral syrup in children aged between 5–11 years. Paediatr Drugs 2004; 6(2): 127–31

    Article  PubMed  Google Scholar 

  24. Tolia V, Han C, North JD, et al. Taste comparisons for lansoprazole strawberry-flavoured delayed-release orally disintegrating tablet and ranitidine peppermint-flavoured syrup in children. Clin Drug Invest 2005; 25(5): 285–92

    Article  CAS  Google Scholar 

  25. Tolia V, Fitzgerald J, Hassall E, et al. Safety of lansoprazole in the treatment of gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr 2002; 35 Suppl. 4: S300–7

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland, 1311, New Zealand

    Katherine F. Croom & Lesley J. Scott

Authors
  1. Katherine F. Croom
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lesley J. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine F. Croom.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Croom, K.F., Scott, L.J. Lansoprazole. Drugs 65, 2129–2135 (2005). https://doi.org/10.2165/00003495-200565150-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200565150-00005

Keywords

Search

Navigation